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Recently, evidence has emerged that seven transmem-
brane G protein-coupled receptors may be present as
homo- and heteromers in the plasma membrane. Here
we describe a new molecular and functional interaction
between two functionally unrelated types of G protein-
coupled receptors, namely the metabotropic glutamate
type 1a (mGlu1a receptor) and the adenosine A1 recep-
tors in cerebellum, primary cortical neurons, and heter-
ologous transfected cells. Co-immunoprecipitation ex-
periments showed a close and subtype-specific
interaction between mGlu1a and A1 receptors in both
rat cerebellar synaptosomes and co-transfected HEK-
293 cells. By using transiently transfected HEK-293 cells
a synergy between mGlu1a and A1 receptors in receptor-
evoked [Ca21]i signaling has been shown. In primary
cultures of cortical neurons we observed a high degree
of co-localization of the two receptors, and excitotoxic-
ity experiments in these cultures also indicate that
mGlu1a and A1 receptors are functionally related. Our
results provide a molecular basis for adenosine/gluta-
mate receptors cross-talk and open new perspectives for
the development of novel agents to treat neuropsychiat-
ric disorders in which abnormal glutamatergic neuro-
transmission is involved.
Glutamate is the major excitatory neurotransmitter in the
central nervous system (1), and its function through ionotropic
and metabotropic (mGlu)1 glutamate receptors can be modu-
lated by other neurotransmitters/neuromodulators (2). Eight
members of the mGlu receptor family have been identified and
categorized into three subgroups on the basis of their sequence
homology, agonist selectivity, and signal transduction path-
way. Group I contains mGlu1 and mGlu5 subtypes, which are
coupled to phospholipase C in transfected cells, and have quis-
qualic acid as their most potent agonist. Five splice variants of
mGlu1 receptor have been described, mGlu1a, mGlu1b, mGlu1c,
mGlu1d, and mGlu1e receptors (3, 4), all of them differing in the
length of their C-terminal tail. The functional significance of
the different splice variants has not yet been fully explored. It
has been suggested that the C-terminal tail, which is intracel-
lular, might play a role in the subcellular targeting of the
receptor (5). Recently, we have reported that the C terminus of
mGlu1a receptor interacts with tubulin (6) and that it can
regulate the cell surface expression of the receptor (7) and its
plasma membrane anchoring (8, 9).
Adenosine is an important neuromodulator implicated in a
variety of brain activities, particularly those related to sleep
and ischemic-hypoxic episodes (10). This ubiquitous nucleoside
exerts its actions via specific receptors, four of which (A1, A2A,
A2B, and A3) have been cloned (11). The A1R is functionally
coupled to members of the pertussis toxin-sensitive family of G
proteins (Gi1, Gi2, Gi3, and Go), and its activation regulates
several membrane and intracellular proteins such as adenylate
cyclase, Ca21 channels, K1 channels, and phospholipase C (11).
Of the multiple neurophysiological actions of adenosine, inhi-
bition of glutamate neurotransmission has been observed in
several brain regions (12) and is probably a result of the inhi-
bition of presynaptic calcium influx (13). Apart from this inhib-
itory effect, there is some evidence documenting functional
interactions between adenosine and glutamate receptors in the
central nervous system. Of particular interest are reports of
group I mGlu receptors signaling being enhanced by group II
mGlu receptors in hippocampal and cerebrocortical slices (14–
16) and by adenosine A1 receptors in cultured hippocampal
type 1 astrocytes (17). Very recently, Toms and Roberts (18)
have described that type 2 astrocytes contain group I mGlu
receptors coupled to [Ca21]i signaling and that co-activation of
adenosine A1 receptors enhances group I mGlu-evoked [Ca21]i
responses in these cells via Gi/o G protein-mediated mecha-
nism. Despite these observations, no clear molecular mecha-
nism of this interaction between glutamate and adenosine re-
ceptors has been provided yet.
Here we report a molecular interaction between metabo-
tropic glutamate receptor type 1a and the adenosine A1 recep-
tor, two members of different GPCR families. This interaction
suggests that both receptors may form part of a signaling
complex in vivo that could play a critical role in fine-tuning
neurotransmission at glutamatergic synapses.
EXPERIMENTAL PROCEDURES
Cell Culture, Generation of mGlu1 Truncated Mutant, and Transfec-
tion—Human embryonic kidney cells, HEK-293, were grown as de-
scribed (9). Rat mGlu1 receptor was truncated after amino acid position
885 (see Fig. 4). A stop codon was introduced into the coding sequence
of the FLAG epitope containing mGlu1a receptor cDNA by polymerase
chain reaction (8). Forward primer was MGR1-F7 (59-GGCCCTGGGG-
TGCATGTTTACTC-39, position 2833–2855 of the mGlu1 receptor cDNA
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(GenBankTM accession number X57569)), and reverse primer was
MGR1-R22 (59-CGTCTCGAGTTTAATTCCCTGCCCCGGGCTTCTTT-
39, position 3026 to 2992, but also encoded XhoI restriction site (under-
lined) and a stop codon (shown in bold)). The BspEI-XhoI fragment of
the amplified cDNA sequence, which contained a stop codon, was used
to substitute corresponding fragment of rat mGlu1a receptor cDNA in
pcDNA3 vector thus resulting in mGlu1-M7 construct (see Fig. 4). The
truncation introduced was confirmed by DNA sequencing.
For the transient expression of mGlu1a, mGlu1b, mGlu1-M7, and/or
A1 receptors, cells were transiently transfected with 10 mg of cDNA
encoding the rat metabotropic glutamate receptors and/or rat adenosine
A1 receptor (ratio 1:1; pcDNA containing LacZ reporter was used to
equilibrate the amount of total DNA) by calcium phosphate precipita-
tion (19). The cells were used for experimentation at either 24 or 48 h
after transfection. Cells were grown in glutamate-free medium (ICN,
Basingstoke, UK) in the absence of both glutamine and glutamic acid
for 3 h before their use.
Primary Cultures and N-Methyl-D-Aspartate (NMDA)-induced Neu-
rotoxicity—Cortical hemispheres from E16 rat embryos were dissected,
and primary cultures of rat cortical neurons were prepared as described
previously (9) and used after 14–21 days in vitro. To determine the
NMDA-mediated neurotoxicity, the culture-conditioned medium was
collected, and the cortical neurons were washed once with serum-free
B27-supplemented Neurobasal medium (Life Technologies, Inc.) con-
taining 50 mg/ml gentamicin (Sigma) (BNG medium) and preincubated
with or without 30 mM NMDA (Tocris, Bristol, UK) for 10 min at 37 °C,
as described previously (20). Quisqualic acid (100 mM) (Tocris, Bristol,
UK) and/or (R)-phenylisopropyladenosine (R-PIA) (100 nM) (Sigma)
were transiently applied for 1 min during the 5 min prior to the addition
of NMDA (20) and then added together with the NMDA. Neurons, after
being washed with the BNG medium, were returned to the culture-
conditioned medium and further incubated at 37 °C for 24 h. After the
NMDA pulse (24 h), neurons were stained with propidium iodide (80
mg/ml) for 5 min and examined immediately with a standard epi-
illumination fluorescence microscope. Neuronal injury was determined
by the ability of propidium iodide (Sigma) to penetrate and interact
with DNA in damaged neurons, yielding red fluorescence.
Immunostaining—For immunohistochemistry, rat cerebellum was
embedded in OCT and frozen in liquid nitrogen-cooled isopentane.
Eight micrometer sections were cut on a cryostat cooled to 218 °C.
Sections were collected onto SuperFrost Plus (BDH, Darmstadt, Ger-
many) slides, air-dried, and stored at 270 °C. Sections were blocked for
30 min in 10% donkey serum in Tris-buffered saline (TBS) (150 mM
NaCl, 50 mM Tris-HCl, pH 7.5). Slides were incubated with affinity-
purified anti-mGlu1a receptor (F2-Ab, 2–4 mg/ml) (21) and affinity-
purified anti-A1R (PC21, 5–10 mg/ml) (22) for 1 h at room temperature
and then washed twice for 5 min in TBS. Fluorescein isothiocyanate-
conjugated donkey anti-rabbit IgG (Jackson ImmunoReserach Labora-
tories Inc., West Grove, PA) was applied in TBS at a dilution of 1:100.
Section were rinsed and mounted with Vectashield immunofluores-
cence medium (Vector Laboratories, Orton Southgate, UK).
For immunocytochemistry, HEK-293 cells transiently transfected
(see above) and primary cultures of rat cortical neurons were fixed in
4% paraformaldehyde for 15 min and washed with phosphate-buffered
saline containing 20 mM glycine (buffer A) to quench the aldehyde
groups. Where indicated, cells were permeabilized with buffer A con-
taining 0.2% Triton X-100 for 5 min. Cells were labeled for 1 h at room
temperature with the indicated primary antibody, washed, and stained
with fluorescein-conjugated donkey anti-rabbit IgG antibody (1/100)
and Texas Red-conjugated donkey anti-mouse IgG antibody (1/100).
Coverslips were rinsed for 30 min in buffer B and mounted with
Vectashield immunofluorescence. Confocal microscope observations
were made with a Leica TCS NT (Leica Lasertechnik GmbH, Heidel-
berg, Germany) confocal scanning laser microscope adapted to an in-
verted Leitz DMIRBE microscope.
Immunoprecipitation—Rat cerebellum synaptosomes (6) or trans-
fected HEK cells were solubilized in ice-cold lysis buffer (phosphate-
buffered saline, pH 7.4, containing 1% (v/v) Nonidet P-40, 0.5% (w/v)
sodium deoxycholic acid, and 0.1% (w/v) SDS) for 1 h on ice. The
solubilized preparation was then centrifuged at 80,000 3 g for 90 min.
The supernatant (1 mg of protein/ml) was processed for immunoprecipi-
tation as described before (6) using the anti-A1R antibody (PC21-Ab) or
anti-FLAG monoclonal antibody (Sigma, Clone M2; 10 mg/ml). The
immune complexes were dissociated in SDS-PAGE sample buffer by
heating to 100 °C for 5 min and resolved by SDS-polyacrylamide gel
electrophoresis in 7% gels (23). Proteins were transferred to polyvinyli-
dene difluoride membranes (Immobilon-P, Millipore, Watford, UK) us-
ing a semi-dry transfer system and immunoblotted using the primary
antibodies indicated in the figure legends and horseradish-peroxidase-
conjugated swine anti-rabbit IgG (Dako, Ely, UK) as a secondary anti-
body. The immunoreactive bands were developed with the enhanced
chemiluminescence detection kit (Pierce), as described previously (6).
Ligand Binding Experiments—Membrane suspensions from tran-
siently transfected HEK cells were obtained according to Casado´ et al.
(24). For competition experiments to determine the KD values, 30 nM
[3H]quisqualic acid (Amersham Pharmacia Biotech) or 20 nM [3H]R-PIA
(Amersham Pharmacia Biotech) binding to membrane suspensions of
HEK cells transiently expressing mGlu1a2FLAG receptor or A1R (0.5
mg protein/ml) were carried out at 25 °C in 50 mM Tris-HCl buffer, pH
7.4, in the absence or presence of increasing amounts of quisqualic acid
or R-PIA, as described previously (24). After 2 h of radioligand incuba-
tion, free and membrane-bound radioligand were separated by rapid
filtration in a Brandel cell harvester through Whatman GF/C filters.
Filters were transferred to scintillation vials containing 10 ml of For-
mula 989 (PerkinElmer Life Sciences). Radioactivity was counted using
a Packard 1600 TRI-CARB scintillation counter with 50% of efficiency.
Competition data were fitted using a non-linear regression program as
described previously (24, 25).
To determine the density of expressed receptors in HEK cells tran-
siently transfected with A1R, mGlu1a-FLAG or A1R plus
mGlu1a2FLAG, the binding of 70 nM [
3H]quisqualic and 15 nM [3H]R-
PIA was performed as described above, and the Bmax was deduced
taking into account the KD values as described previously (24).
Calcium Determination—Transiently transfected HEK cells (106 cell/
ml) were loaded with 5 mM Fura-2/AM for 30 min at 37 °C. Cells were
washed and subsequently incubated in HBSS containing 0.2 units/ml
adenosine deaminase. Calcium peak induction was achieved by the
addition of R-PIA or quisqualic acid. Intracellular calcium was deter-
mined at 37 °C in a dual-wavelength Shimadzu RF-5000 spectrofluoro-
photometer (Shimadzu Europe, Duisberg, Germany) by using the exci-
tation wavelength ratio of 334/366 nm with emission cut-off at 500 nm.
Free calcium concentration was calculated as described previously (26).
RESULTS
Interaction of mGlu1a and A1 Receptors in Rat Cerebellum—
Immunohistochemical studies showed that mGlu1a receptors
are present in cerebellum, and its expression is mainly re-
stricted to the cell body and the dendritic tree of Purkinje cells
and basket cells located in the molecular layer (Fig. 1a). This is
in agreement with the previously described location of these
receptors in an annulus, which surrounds the post-synaptic
density (27). The A1R had a more ubiquitous distribution in
cerebellum being expressed in Purkinje cells and basket cells,
as mGlu1a receptor, and also in granule cells (Fig. 1a). This fits
with the localization of adenosine A1 receptors both presynap-
tically and postsynaptically (28). In addition, metabotropic glu-
tamate receptor type 1a and adenosine A1 receptors showed a
similar distribution in human cerebral cortex being expressed
in large pyramidal cells located at layers V and II/III (data not
shown).
The in vivo co-distribution of mGlu1a and A1 receptors in
some cerebellar neurons (Fig. 1a) suggests a potential interac-
tion between both receptors at precise brain areas. The exist-
ence of mGlu1a/A1 receptors’ heteromers was assayed by co-
immunoprecipitation experiments using a soluble extract from
rat cerebellum synaptosomes that had been shown by Western
blotting to contain both adenosine A1 (Fig. 1b, lane 1) and
mGlu1a receptors (Fig. 1b, lane 2). When this soluble extract
was immunoblotted using a specific antibody against A1 recep-
tor (PC21-Ab), two bands of around 39 and 74 kDa of molecular
size were shown (Fig. 1b, lane 3); these bands, which are
glycosylated proteins (29), have been demonstrated previously
to correspond to the adenosine A1 receptor monomer and
dimer, respectively (22). On the other hand, a specific antibody
against the mGlu1a receptor (F2-Ab) immunoblotted in the
cerebellum synaptosomes extract a band with apparent molec-
ular size of 150 kDa that corresponds to the mGlu1a receptor
(Fig. 1b, lane 4), which is a glycosylated protein as it has been
described previously (21, 30). From this extract, the antibody
against A1R (PC11-Ab) immunoprecipitated a band of 150 kDa
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that was detected by the F2-Ab (Fig. 1b). This band was also
immunoprecipitated using a different antibody against mGlu1
receptor (F1-Ab) but was not present in immunoprecipitates
generated with an irrelevant antibody (Fig. 1b, lane 5). It
should be noted that the efficacy of immunoprecipitation of
mGlu1a receptor by the anti-adenosine receptor antibody was
much less than when an anti-mGlu1 receptor antibody was
used. Overall, these results indicate that there are zones in
which mGlu1a and A1 receptors do not co-distribute and that
there are zones in which the two receptors co-distribute and
form aggregates (heteromers).
Interaction of mGlu1a and A1 Receptors in Transiently
Transfected HEK-293 Cells—The close association of mGlu1a
and A1 receptors was subsequently studied in co-transfected
HEK-293 cells by co-immunoprecipitation and double immuno-
labeling experiments. By confocal microscopy analysis of HEK-
293 cells transiently transfected with the cDNAs for mGlu1a-
FLAG and A1 receptors, a marked overlap in the distribution of
the two proteins was found (Fig. 2). As deduced from horizontal
optical sections of permeabilized (1Triton) and nonpermeabi-
lized (2Triton) cells, co-localization was not restricted to the
plasma membrane but extended to intracellular compart-
ments. Interestingly, when the double immunolabeling exper-
iment was performed on HEK-293 cells transiently transfected
with the cDNAs for mGlu1b-FLAG, the C-terminal splice vari-
ant of mGlu1 receptor (Fig. 4a), and A1 receptors, no co-local-
ization between both proteins was observed at the plasma
membrane level (Fig. 2), suggesting a specificity for the co-
localization between mGlu1a-FLAG and A1 receptors.
From co-transfected HEK cell extracts, the antibody against
A1R (PC11-Ab) co-immunoprecipitated a band of 150 kDa,
which corresponds to the mGlu1a-FLAG receptor (Fig. 3, lane
5). This band did not appear in immunoprecipitates from cells
transfected with the cDNA for either A1 receptors (Fig. 3, lane
4) or mGlu1a (Fig. 3, lane 6) or when an irrelevant antibody was
used (data not shown). Conversely, when we immunoprecipi-
tate with the FLAG antibody to pull down mGlu1a-FLAG re-
ceptor in the transiently co-transfected HEK-293 cells, and
subsequently the immunoprecipitates were analyzed by SDS-
PAGE and immunoblotted using anti-A1R antibodies, a band
which corresponds to the A1R was observed (Fig. 3, lane 11).
Interestingly, no immunoprecipitation of mGlu1b receptor, the
C-terminal splice variant of mGlu1 receptor (Fig. 4a), was ob-
tained from co-transfected cells using the antibody against A1R
(PC11-Ab) (Fig. 4b, lane 7). Additionally, the construct mGlu1-
M7, a deleted mutant close to the splice variant site of the
mGlu1 receptor (Fig. 4a), also did not interact with A1R (Fig.
4b, lane 8). Overall, these results suggest that the C-terminal
tail of the mGlu1a receptor (Fig. 4a) is implicated in the inter-
action of both receptors.
To test the functional significance of an mGlu1a/A1 receptors
interaction, measurements of calcium mobilization in co-trans-
fected HEK-293 cells were performed. In HEK cells transiently
expressing A1R or A1R plus mGlu1a-FLAG R-PIA mobilized
intracellular calcium in a concentration-dependent manner,
with an EC50 value of 46.8 6 4.4 nM for the single expressing
A1R cells or 45.7 6 5.1 nM for the doubly A1R plus mGlu1a-
FLAG expressing cells. On the other hand, in these cells quis-
qualicacidalsomobilizedintracellularcalciuminaconcentration-
dependent manner, with an EC50 value of 4.1 6 1.1 mM for the
single expressing mGlu1a-FLAG cells or 5.6 6 1.1 mM for the
doubly A1R plus mGlu1a-FLAG expressing cells. The densities
of the transiently expressed receptors were controlled by
FIG. 1. Interaction of mGlu1a and A1 receptors in rat cerebel-
lum. a, 8-mm cryosections from rat cerebellum were stained with anti-
mGlu1a receptor antibody (F2-Ab; 4 mg/ml) and anti-A1R antibody
(PC21-Ab; 10 mg/ml). F2-Ab immunoreactivity is confined mainly to the
molecular layer (ML) and it stains Purkinje cells and basket cells.
PC21-Ab stains Purkinje cells and basket cells in the molecular layer as
well as granule cells in the granular layer (GL). b, co-immunoprecipi-
tation of mGlu1a and A1 receptors from extracts of rat cerebellum
synaptosomes. Extracts and immunoprecipitates (IP) (see “Experimen-
tal Procedures”) were analyzed by SDS-PAGE and immunoblotted (IB)
using anti- mGlu1a receptor antibodies (F2-Ab; 5 mg/ml) or anti-A1R
antibodies (PC11-Ab; 10 mg/ml). Immunoreactive bands were detected
with swine anti-rabbit (1:5000) secondary antibody conjugated to horse-
radish peroxidase followed by chemiluminescence detection. IgG
indicates the position of the immunoglobulins used in the
immunoprecipitation.
FIG. 2. Immunofluorescence localization of mGlu1a, mGlu1b,
and A1 receptors in HEK-293 cells. Cells were transiently trans-
fected with cDNAs encoding for mGlu1a2FLAG or mGlu1b2FLAG and
A1R. After 48 h cells were washed, fixed (2Triton), and/or permeabi-
lized (1Triton) and processed for immunostaining with anti-FLAG
monoclonal antibody (Sigma, Clone M2; 10 mg/ml) and anti-A1R affin-
ity-purified antibody (PC21-Ab, 5 mg/ml). The bound primary antibodies
were detected using either fluorescein-conjugated donkey anti-mouse
IgG antibody (1/50) or Texas Red-conjugated donkey anti-rabbit (1/50).
Cells were analyzed by double immunofluorescence with a confocal
microscopy. Superimposition of images reveals mGlu1a (green) and A1
(red) receptors co-localization in yellow. The images show a single
horizontal section of representative cells. Scale bar, 10 mm.
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means of ligand binding experiments performed in these cells
(see “Experimental Procedures”). Cells transfected with the
cDNA for A1R alone express 3.4 6 0.4 pmol of A1R/mg protein
as detected by [3H]R-PIA binding with a KD of 27 6 3 nM. In
these cells the A1R agonist R-PIA leads to a calcium peak (Fig.
5). On the other hand, cells transfected only with the cDNA for
mGlu1a receptor express 3.3 6 0.9 pmol of mGlu1a receptor/mg
protein as detected by [3H]quisqualic binding with a KD of
177 6 46 nM, and a weak calcium peak was detected when
treated with the agonist for the metabotropic glutamate recep-
tor, quisqualic acid (Fig. 5). Interestingly, in HEK-293 cells
co-transfected with both receptors (3.3 6 0.2 pmol of A1R/mg of
protein and 2.8 6 1.5 pmol of mGlu1a/mg of protein), preincu-
bation with quisqualic acid markedly potentiated the calcium
peak obtained in response to A1R activation (140 6 10%; n 5
3). Conversely, preincubation of co-transfected cells with the
agonist for A1R led to a marked enhancement of the signal
provided by quisqualic acid (180 6 20%; n 5 3) (Fig. 5). Quis-
qualic acid or R-PIA failed to bind or to provide any signal in
nontransfected HEK-293 cells. These results clearly show a
heterologous sensitization or synergistic effect upon mGlu1a
and A1 receptors activation.
Interaction of mGlu1a and A1 Receptors in Primary Rat Cor-
tical Neurons—To assess the physiological relevance of the
mGlu1a/A1 receptors interaction, we analyzed the distribution
of both receptors in primary rat cortical neurons. Both recep-
tors showed a similar punctate distribution throughout the
proximal and distal dendrites, and the degree of co-localization
at these locations was very high (Fig. 6, a–c). In fact, some of
the mGlu1a receptor2 or A1R-containing puncta co-distributed
with the synaptic marker protein synaptophysin (Fig. 6, d–i),
suggesting that they could be localized to synapses. Thus, syn-
apses are one of the specific cellular sites where mGlu1a and A1
receptors interact.
Glutamate/adenosine receptors interaction may be impor-
tant for modulating the role of mGlu1a receptor in neurodegen-
eration/neuroprotection, an issue that is still controversial.
When examining this role a number of factors, including the
FIG. 3. Interaction of mGlu1a and A1 receptors in transiently
transfected HEK-293 cells. Cells transiently expressing A1R alone
(lanes 1 and 7), A1R plus mGlu1a2FLAG (lanes 2 and 8), or mGlu1a-
FLAG alone (lanes 3 and 9) were washed and solubilized in ice-cold lysis
buffer and processed for immunoprecipitation using anti-A1R antibod-
ies (PC11-Ab; 10 mg/ml; lanes 4–6) and anti-FLAG monoclonal antibody
(Sigma, Clone M2; 10 mg/ml; lanes 10–12). Solubilized membranes
(Crude, lanes 1–3 and 7–9) and immunoprecipitates (IP, lanes 4–6 and
10–12) were analyzed by SDS-PAGE and immunoblotted (IB) using
anti-mGlu1a receptor antibodies (F2-Ab; 5 mg/ml) or anti-A1R antibod-
ies (PC21-Ab; 10 mg/ml). Immunoreactive bands were detected as be-
fore. IgG indicates the position of the immunoglobulins used in the
immunoprecipitation.
FIG. 4. Specificity of the interaction between mGlu1a and A1
receptors in transiently transfected HEK-293 cells. a, schematic
representation of the primary structure of rat mGlu1a and mGlu1b
receptors. The gray arrowhead indicates the position of the stop codon
introduced to generate the deleted mutant mGlu1-M7. b, HEK-293 cells
transiently expressing A1R alone (lane 1), A1R plus mGlu1a2FLAG
(lane 2), A1R plus mGlu1b-FLAG (lane 3), and A1R plus mGlu1-M7-
FLAG (lane 4) were processed for immunoprecipitation using anti-A1R
antibodies (PC11-Ab; 10 mg/ml). Solubilized membranes (Crude, lanes
1–4) and immunoprecipitates (IP, lanes 5–8) were analyzed by SDS-
PAGE and immunoblotted (IB) using anti-mGlu1 antibodies (F1-Ab; 5
mg/ml). Immunoreactive bands were detected as before. IgG indicates
the position of the immunoglobulins used in the immunoprecipitation.
FIG. 5. Ca21 mobilization in HEK-293 transiently expressing
mGlu1a and A1 receptors. Intracellular Ca
21 concentrations were
measured in suspended cells loaded with FURA-2/AM after stimulation
with the mGlu1a receptor agonist quisqualic acid (100 mM) (Quis) or A1R
agonist N6-(R)-phenylisopropyladenosine (500 nM) (R-PIA).
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heteromeric composition of NMDA receptors, the time of expo-
sure to drugs or to ambient glutamate, and the function of
astrocytes clearing extracellular glutamate and producing neu-
rotoxic or neuroprotective factors must be taken into account
(20). On the other hand, glutamate could also modulate the
well known function of adenosine as neuroprotective factor
(12). It is thus likely that the interaction of mGlu1a/A1 recep-
tors could be beneficial in situations of enhanced neuronal
activity, in which potentiation of postsynaptic adenosine A1
receptor limits evoked depolarization and results in decreased
activation of voltage-dependent Ca21 channels and NMDA re-
ceptor ion channels, through which Ca21 enters cell bodies (30).
We have therefore examined the effect of activating of both
mGlu1 and A1 adenosine receptors on NMDA-mediated neuro-
toxicity in primary neuronal cultures. In agreement with pre-
viously described data (20), submaximal concentrations of
NMDA induced neuronal death, which was enhanced by the
presence of quisqualic acid during the NMDA treatment (Fig.
7). In contrast, when the adenosine A1 receptor agonist, R-PIA,
was present during the NMDA treatment, the induced neuro-
toxicity was reduced by nearly 50%. When added simulta-
neously, R-PIA reduced the enhancement of the neurotoxicity
induced by quisqualic acid (Fig. 7). On the other hand, pre-
exposure of neurones to R-PIA or to quisqualic acid also re-
duced the NMDA-induced neurotoxicity. This reduction was
more marked if both quisqualic acid and R-PIA were present
during the pre-exposure, showing that the simultaneous acti-
vation of both receptors appears to increase the protection of
the neurones against the NMDA treatment compared with the
effect evoked by either quisqualate or R-PIA applied sepa-
rately. These results show the relevance of the interaction of
mGlu1a/A1 receptors and support the concept of specificity and
complexity of this interaction, being the spatiotemporal segre-
gation profile of adenosine/glutamate during synaptic activity
of special importance to achieve a neuroprotective or a neuro-
toxic effect.
DISCUSSION
Here we describe a novel interaction between two unrelated
G protein-coupled receptors (GPCR), namely the metabotropic
glutamate type 1a and the adenosine A1 receptors. Although
the cooperativity of the agonist binding to GPCR suggested the
possibility of oligomerization of G proteins and their associated
receptors (31), the existence and the precise function of GPCR
homo- or heteromerization has not been fully elucidated.
Metabotropic glutamate type 1a and adenosine A1 receptors
show a high degree of co-localization in co-transfected cells and
in more physiological systems as neurons from rat cerebellum
and from rat cortex. Both receptors co-immunoprecipitate from
co-transfected cells and from rat cerebellum synaptosomes,
FIG. 7. Excitotoxicity in rat cortical neurons. Cortical neurons
were exposed for 10 min to 30 mM of NMDA. Quisqualic acid (Quis, 100
mM) and/or R-PIA (100 nM) were transiently applied (for 1 min) 5 min
prior to the addition of NMDA (Pre-exposure) and/or added together
with NMDA for 10 min (Treatment). Quisqualic acid treatments were
always made in the presence of 50 mM 6-cyano-7-nitroquinoxaline-2,3-
dione (CNQX, Sigma) to block non-NMDA receptors. Death neurons
were computed by assessing the propidium iodide staining in photomi-
crographs of 10 representative fields from each monolayer of treated
neurons and expressed as percent of NMDA toxicity. Asterisks denote
differences from the control (*, p , 0.05; **, p , 0.01, two-tail t test).
FIG. 6. Co-localization of mGluR1a
and A1R in primary cultures of rat
cortical neurons. Neurons (days in vitro
14–21) were fixed, permeabilized, and
processed for immunostaining using rho-
damine-conjugated anti-A1R antibody
(PC21-Ab; 15 mg/ml) and fluorescein-con-
jugated anti-mGlu1a receptor antibody
(F2-Ab; 15 mg/ml) (a–c), anti-A1R anti-
body (PC21-Ab, 5 mg/ml) and anti-synap-
tophysin monoclonal antibody (1/20) (d–f),
or anti-mGlu1a receptor antibody (F2-Ab;
5 mg/ml) and anti-synaptophysin mono-
clonal antibody (1/20) (g–i). Primary anti-
bodies in d–i were detected using fluores-
cein-conjugated donkey anti-mouse IgG
antibody (1/50) or Texas Red-conjugated
donkey anti-rabbit (1/50)(d–i). Cells were
analyzed by double immunofluorescence
with a confocal microscopy. Images show
A1R receptor (a) in red mGlu1a receptor
(b) in green, A1R (d) and mGlu1a (g) re-
ceptors in red, and synaptophysin (h) in
green. Superimposition of images reveals
co-localization in yellow (c, f, and i). Scale
bar, 10 mm.
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suggesting that mGlu1a and A1 receptors interact and that this
interaction is physiologically relevant. From a functional point
of view, heteromerization often results in facilitatory responses
or synergistic effects. Thus, GABABR1 and GABABR2 recep-
tors need to be co-expressed and assembled into heteromers to
reach the cell surface (32–35). On the other hand, two func-
tional opioid receptors, k and d, can heteromerize, which
changes the pharmacology of the individual receptors and po-
tentiates signal transduction (36). Also, it has been described
for heterodimerizations for the CC chemokine receptor 2
(CCR2) and the CX chemokine receptor 4 (CXCR4) and/or CC
chemokine receptor 5 (CCR5) (37). Recently, it has been dem-
onstrated that k and d opioid receptors can form heteromers
with b2-adrenergic receptors affecting their trafficking proper-
ties without any significant alteration in the ligand binding or
coupling properties of the receptors (38). There are also some
papers reporting similar interactions between GPCR and non-
GPCR proteins, for example the receptor activity-modifying
protein, a small protein containing only one putative trans-
membrane domain and a short cytosolic tail, acting as a chap-
erone protein that facilitates the cell surface targeting and
modulator function of the calcitonin-receptor-like receptor (39).
Interestingly, recent data (40) indicated that a GPCR, the
D5-dopamine receptor, physically interacts with the g-ami-
nobutyric acid A (GABAa) receptor, a GABA-operated Cl2
channel. This physical interaction was dependent on the pres-
ence of agonist for both receptors and necessary for the func-
tional cross-talk between the D5 and GABAa receptors (40). In
the case of cells co-expressing mGlu1a and A1 receptors, a
glutamate/adenosine synergism was found at the level of cal-
cium mobilization (Fig. 5). Furthermore, in experiments of
neuroprotection performed in neuronal cultures, preincubation
with quisqualic acid plus adenosine was much more effective
than pretreatment with any of the compounds. These results
suggest that activation of mGlu1a and A1 receptors in the same
neuron results in synergism. Heteromerization, however, does
not always lead to facilitation or synergistic events. Thus, in
basal ganglia, there is an adenosine-mediated antagonism of
dopaminergic neurotransmission. This antagonism is in part
due to cross-talk at the level of second messengers but is also
mediated by formation of adenosine/dopamine receptor hetero-
mers (41). Although it is difficult to ascertain to what extent
the antagonism is mediated by heteromerization or to interfer-
ence in signaling, there is evidence indicating that both events
operate and are closely interrelated. Thus, in cells where A1R
and D1-dopamine receptors are present, as in nigrostriatal
GABAergic neurons, adenosine leads to both the disappearance
of the high affinity site of D1 receptors, probably via conforma-
tional changes in A1R/D1R heteromers, and a reduction in
dopamine-induced cAMP increases, an effect due to cross-talk
at the adenylate cyclase level (41).
There is experimental and molecular modeling evidence that
intramembrane domains are involved in the formation of ho-
modimers of G protein-coupled receptors. Gouldson et al. (42)
have hypothesized that domain swapping with involvement of
transmembrane regions 5 and 6 is responsible for homo- and
heteromerization of G protein-coupled receptors. In contrast,
heterodimerization of GABAR1 and GABABR2 receptors is
mediated by the coiled-coil interaction of the C-terminal cyto-
plasmic tails (35). In the case of mGlu1a/A1 receptors’ hetero-
mers the interaction depends on the C terminus of mGlu1a
receptor as its splice variant, mGlu1b receptor, which has a
short and different C terminus, does not interact with A1R.
Also a deleted mutant of mGlu1 receptor, close to the splice
variant site and missing nearly all the C terminus of the
receptor, does not interact with A1R. The co-immunoprecipita-
tion of mGlu1a and A1 receptors might be due to a physical
association between them, but it also could be the case that
both receptors are recruited into a specific signaling complex at
specific synapses via common interactions with other proteins.
One possible mechanism for this mGlu1a/A1 receptor cou-
pling is that it is directed by interactions of the cytoplasmic C
terminus with specific targeting proteins. This type of target-
ing mechanism appears to operate for the synaptic localization
of the ionotropic glutamate receptors and a number of different
proteins, containing PDZ domains, which interact with specific
C-terminal sequences of these receptors (43–47). Also, the
EVH1-like domain (ENA/VASP homology domain 1)-contain-
ing protein, which binds specifically to the C-terminal residues
of mGlu1a receptor, has been described (48). This protein,
termed Homer-1A, was isolated as a synaptic plasticity-regu-
lated gene from rat hippocampus (48, 49). Additional proteins
related to Homer-1A have also been described, namely Homer-
1B, Homer-1C, Homer-2A, Homer 2B, Homer-2C, Homer-2D,
Homer-3A, Homer-3B, Homer-3C, and Homer-3D (50–53). The
ability of Homer to link mGlu1a receptor to Shank, a scaffolding
multimeric signaling protein, may contribute to anchoring the
mGlu1a receptor to specific sites at the plasma membrane (8,
9). Our efforts are directed to find a network of protein inter-
actions that are shared by both receptors and that likely play a
key role in the signaling mechanisms of both mGlu1a and A1
receptors. The nature of the signaling complexes formed would
depend on the type of receptors present in a given neuron, and
the effect will be determined by the balance between concen-
trations of agonists in the synaptic cleft and timing of receptor
activation. It has been proposed that the mechanism of the
biphasic effects of quisqualic acid to increase NMDA toxicity if
added together with NMDA or to reduce it if pretreated before
NMDA is in part due to the functional switch described for the
mGlu1a receptor (54, 55, 20). In mixed cortical or pure hip-
pocampal neuronal cultures a first application of 3,5-dihy-
droxyphenylglycine, an agonist of the group I mGlu receptors,
potentiated toxicity induced by submaximal concentrations of
NMDA, whereas the same drug applied shortly after a brief
pre-exposure, protected against neuronal death (20). Interest-
ingly, the switch in the regulation of excitotoxic neuronal death
was sensitive to protein kinase C inhibitors (20). This mecha-
nism may explain the opposite results obtained with group I
mGlu receptors, assuming that the influence of group I mGlu
receptors on excitotoxic neuronal death will depend on the
“functional status” of group I mGlu receptors (naive versus
experienced or unphosphorylated versus phosphorylated recep-
tors) (20). In Fig. 7 we show that the timing in mGlu1a and A1
receptors activation is very important to achieve a maximum
effect in adenosine- and glutamate-mediated neuroprotection/
neurodegeneration. In fact, although adenosine added together
with glutamate was protective for cultured neurons, this pro-
tection was nearly total by preincubation with the metabo-
tropic glutamate receptor agonist.
Our data provide biochemical and functional evidence for
mGlu1a and A1 receptor-receptor interaction. The way A1R is
involved in interactions with receptors for other neurotrans-
mitters, using different receptor system to synchronize synap-
tic transmission, opens new perspectives to understand the
actual role of this autacoid. Since mGlu1a receptors seem to be
involved in the pathophysiology of neuropsychiatric diseases
such as Alzheimer’s and related disorders, this molecular in-
teraction offers a new basis for the design of novel strategies to
study the genesis and evolution of these diseases and of novel
agents to treat them.
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